

**CPDD, RSA & LSU Joint Program**  
**Session (1) Thursday, June 19, 2025**  
**Session (2), Friday, June 20, 2025**

**Featured Keynote Speaker:**

The National Drug Early Warning System Networks, Initiatives and Data: How can we Help  
Linda Cottler, Ph.D., MPH, FACE

**Polysubstance Use Involving Alcohol and Cannabinoids**

**Lindsay Squeglia (Chair), Leanne Hides (Speaker), Jane Metrik (Speaker), Lara Ray (Speaker), Katherine Keyes (Speaker), Rajesh Miranda (Speaker)**

The First Step Brief Intervention for Polysubstance Use in Community Alcohol and Other  
Drug Treatment Services

Leanne Hides, Ph.D., University of Queensland

Cannabis and Alcohol Co-Use: Translational Perspectives From the Laboratory to Daily Life  
Jane Metrik, Ph.D., Brown University School of Public Health

Alcohol and Cannabis Co-Use: Insights From Behavioral Pharmacology and Neuroimaging  
Lara Ray, Ph.D., University of California Los Angeles

Epidemiology of Polysubstance Use in the United States: Trends in Adolescence and  
Adulthood

Katherine Keyes, Ph.D., MPH, Columbia University

Consequences of Maternal Alcohol and Cannabinoid Co-Exposures on Behavior and Gut  
Metabolism in Adult Offspring

Rajesh Miranda, Ph.D. Texas A&M University College of Medicine

**Polysubstance Use Involving Alcohol and Opioids**

**Lori Knackstedt, (Chair), Sandra Comer (Speaker), Richard Grucza (Speaker) Donna  
Platt (Speaker), Katie Witkiewitz (Speaker), Brady Atwood (Speaker)**

Co-Use of Opioids and Alcohol: Gabapentin as a Potential Treatment

Sandy Comer, Ph.D., Columbia University and NYSPI

Trends and Disparities in Alcohol-Related Liver Disease Mortality, 2001–2020: Beyond Deaths of Despair

Richard Gruzca, Ph.D., MPE, Saint Louis University

Alcohol, Opioids, and Their Co-Use: Influence of OPRM1

Donna Platt, Ph.D., University of Mississippi Medical Center

The Impact of Opioids and Alcohol on Tau Proteins and Synaptic Function

Brady Atwood, Ph.D., University of Minnesota

Behavioral Approaches to Treatment of Opioid Use, Alcohol Use, and Pain

Katie Witkiewitz, Ph.D., University of Mexico

**The Incretin System as a Therapeutic Target for the Treatment of Substance Use Disorders**

**Christian Hendershot (Chair), Scott Bunce (Speaker), Phillip Coffin (Speaker), Shirley Pinto (Speaker), Christian Hendershot (Speaker)**

Activation of Gut Enteroendocrine Cells With the Combination of GPR119 Agonist K-833 And GRP40 Agonist K-757 Results in Synergistic Hormone Secretion in Murine Models and Humans

Shirly Pinto, Ph.D., Kallyope

The Incretin System as a Therapeutic Target for the Treatment of Substance Use Disorders

Scott Bunce, Penn State University College of Medicine and Penn State Medical Center

Testing GLP-1 Agents for Substance Use Disorders: Focus on Stimulant Use

Phillip Coffin, San Francisco Department of Public Health

The Incretin System as a Therapeutic Target for the Treatment of Substance Use Disorders

Christian Hendershot, University of South California Keck School of Medicine